

<b>Interests Register</b>	<b>Register last updated: 15/07/2021</b>
<b>Advisory Committee: PHAC D Managing Common Infections</b>	
<b>Guideline: <i>Clostridioides difficile</i> infection: antimicrobial prescribing</b>	

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Stephanie Dancer	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	None	N/A	15/02/2019	N/A	N/A
Yarni Finney	PHAC D Advisory Committee Topic Expert Lay Member	Direct - financial	Member of the NICE Public Involvement Programme Expert Panel.	Jul-20	01/09/2020	Ongoing	Declare and participate.
Yarni Finney	PHAC D Advisory Committee Topic Expert Lay Member	Direct - financial	Lay representative to Health Education England North West for Doctors in core and speciality training. Paid honorarium.	May-19	27/06/2019	Ongoing	Declare and participate.
Alastair Hay	PHAC D Advisory Committee Member	Direct - financial	Co-authoring 'Rational use of antibiotics': BMJ Learning modules	01/05/2020	01/05/2020	Ongoing	Declare and participate at the chair's discretion.
Alastair Hay	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Member of the APRHAI (Antimicrobial Prescribing and Resistance, and Healthcare Associated Infections) Government Advisory Committee.	2013	18/05/2017	Sep-18	Declare and participate at the chair's discretion

Alastair Hay	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	University academic who has published extensively in the field, could be perceived as having an interest in seeing work cited in the NICE guideline. However, primary interest is to promote the safe, effective and judicious use of antibiotics in order to preserve their effectiveness for future generations	1997	12/11/2016	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to published papers.
Alastair Hay	PHAC D Advisory Committee Member	Indirect	Attended meeting convened by Pfizer to discuss research projects looking to establish the community burden of vaccine preventable illness. No payment or contracting at present (Mar 2019)	Jan-19	20/03/2019	Ongoing	Declare and participate at the chair's discretion
Alastair Hay	PHAC D Advisory Committee Member	Indirect	Co-investigator on a Merck project to investigate the burden of vaccine preventable ear infections in children.	Jul-20	01/07/2020	Ongoing	Declare and participate.
Alastair Hay	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Invited to write an editorial by the BMJ which commented on two studies; concerning antibiotic management in UTI (doi:10.1136/bmj.l525) and duration of antibiotic treatment (doi.org/10.1136/bmj.l440)	Jan-19	20/03/2019	Mar-19	Declare and participate at the chair's discretion
Ian Hill-Smith	PHAC D Advisory Committee Member	Direct - financial	Potential increase in income from own educational courses and publications, should professional standing and reputation improve as a result of working with NICE.	02/03/2018	12/05/2018	Ongoing	Declare and participate ensuring specific interests are declared as they arise whilst taking advice from NICE as necessary
Ian Hill-Smith	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Director of the National Minor Illness Centre	02/03/2018	22/01/2018	Ongoing	Declare and participate at the chair's discretion
Ian Hill-Smith	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	One of the authors of The Minor Illness Manual. Fifth edition published 21 November 2018.	02/03/2018	12/05/2018	21/11/2018	Declare and participate at the chair's discretion

Ian Hill-Smith	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	One of two authors of Little Book of Red Flags which is about diagnosis in primary care, focusing on how to recognise the symptoms of serious disease. Treatment is not covered except by way of explanation of the need for referral. For example, certain people with shingles benefit from antiviral medication and this affects why a person may need to be referred from community pharmacy to their GP. No specific prescribed medicines are mentioned. A few over-the-counter treatments are mentioned with regards to their effectiveness, in so far as whether this would affect whether referral is needed or not (e.g. Vicks Vaporub®, Metanium®, Bepanthen®)	18/11/2018	16/01/2019	05/02/2019	Declare and participate at the chair's discretion
Susan Hopkins	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines BMJ 2019; 364 doi:	31/01/2019	31/01/2019	27/02/2019	Declare and participate at the chair's discretion
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Powell, N.; Howard, P.; Llewelyn, M.J. et al (2021) "Use of Procalcitonin during the First Wave of COVID-19 in the Acute NHS Hospitals: A Retrospective Observational Study" Antibiotics 2021, 10, 516. <a href="https://doi.org/10.3390/antibiotics10050516">https://doi.org/10.3390/antibiotics10050516</a>	2021	11/05/2021	01/05/21	Declare and participate.

Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	President of British Society of Antimicrobial Chemotherapy. BSAC provides free education and research funding on the responsible use of antibiotics to healthcare professionals, public and Parliamentarians within its charitable goals at a global level. Part of BSAC's income is from the pharmaceutical and diagnostics industry through unrestricted education grants. All financial elements dealt with by CEO and Treasurer.	Apr-18	31/05/2019	Ongoing	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Royal Pharmaceutical Society Antimicrobial Expert Advisory Board. Provide advice to RPS about AMR and antimicrobial stewardship. Occasional spokesperson.	2016	31/05/2019	Ongoing	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	National AMR project lead for NHS-Improvement secondment.	Nov-14	31/05/2019	Mar-19	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	UKCPA Trustee & Pharmacy Infection Network Committee member. Professional network of hospital pharmacists working in AMS.	2002	31/05/2019	Ongoing	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	University academic & clinical pharmacist who has published extensively in the field, could be perceived as having an interest in seeing work cited in the NICE guideline. However, primary interest is to promote the safe, effective and judicious use of antibiotics in order to preserve their effectiveness for future generations	2009	31/05/2019	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to published papers.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	European Society of Clinical Microbiology and Infectious Diseases AMS Group committee member	2016	31/05/2019	Ongoing	Declare and participate.

Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Spoke at a Pfizer sponsored panel on antibiotic delinkage at RCP conference. No fee or travel expenses. (Fellow panel included NICE Economist).	Apr-19	31/05/2019	Apr-19	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial / financial professional and personal	Astellas funded research grant to undertake study for this paper: Goldenberg, S. D, Brown, S., Edwards, L., Gnanarajah, D., Howard, P et al. (2016). "The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations." Eur J Clin Microbiol Infect Dis 35(2): 251-259. Paper won Prix Galien Prize for Real World Evidence.	Jul-05	19.12.19	2016	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	HEE AMR grant to test an Antibiotic checklist in community pharmacy.	Nov-19	31/0//2019	Ongoing	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	NIHR-PGfR (Ref number RP-PG-1214-20007) Grant for Penicillin allergy status and its effect on antimicrobial prescribing, patient outcomes, and antimicrobial resistance. Short title: ALABAMA: Allergy, Antibiotics and Microbial Resistance. Co-applicant	2015	31/05/2019	Ongoing	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Talk at IAMMAC conference in Moscow for BSAC on antibiotic education	May-19	31/05/2019	May-19	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Talk at Royal Cornwall Hospital on One Health antibiotic use	May-19	31/05/2019	May-19	Declare and participate.
Philip Howard	PHAC D Advisory	Direct - non-financial	Talk on human AMR at British Society of Animal science	Apr-19	31/05/2019	Apr-19	Declare and participate.

	Committee Member	professional and personal					
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Antimicrobial stewardship – everybody's business. Isle of Man IPC conference.	Feb-19	31/05/2019	Feb-19	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	BSAC AMS education activities. HEE AMR Conference. London	Dec-18	31/05/2019	Dec-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Webinar for Romanian Schools of Pharmacy on Antimicrobial Stewardship.	Dec-18	31/05/2019	Dec-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Achievement and experience in combatting AMR in UK. Ukrainian 1st international AMR conference. Ukraine	Nov-18	31/05/2019	Nov-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	What's the value in measuring antimicrobial consumption at a OneHealth level. OneHealth AMR conference. London	Oct-18.	31/05/2019	Oct-18.	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Antimicrobial Stewardship. Romanian Hospital Pharmacy Association. Bucharest.	Sep-18	31/05/2019	Sep-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Update on progress on AMR in England. AMR Insight. Dublin.	Jun-18	31/05/2019	Jun-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	WHO EML AWaRe at Wales AMS Forum. Cardiff.	May-18	31/05/2019	May-18	Declare and participate.

Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Role of the Pharmacist in AMR (for FIP). Panel at World Forum on Public Health Associations. Geneva.	May-18	31/05/2019	May-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	South West AMS Group. Merging sepsis with AMS. Taunton.	May-18	31/05/2019	May-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Talk on AMR progress. Microbes Den. MSD AMR conference. London.	May-18	31/05/2019	May-18	Declare and participate.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Sandoe et al. JAC 2019. "Warning: allergic to penicillin." Association between penicillin allergy status in 2.3 million NHS general practice electronic records, antibiotic prescribing, and health outcomes.	Mar-19	31/05/2019	Mar-19	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	NIHR BATCH study (procalcitonin in children)	2018	31/05/2019	Ongoing	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Research paper. Limmathurotsakal et al. JAC 2019. Antibiotic footprint: a communication tool to aid reduction of antimicrobial reduction.	Apr-19	31/05/2019	Apr-19	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Research paper: Thornley et al. JAC 2019 Antimicrobial use in long term facilities – the results of a point prevalence study.	Apr-19	31/05/2019	Apr-19	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Research paper: Hood et al. Measuring Appropriate Antibiotic Prescribing in Acute Hospitals: Development of a National Audit Tool Through a Delphi Consensus	Apr-19	31/05/2019	Apr-19	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory	Direct - non-financial	Research paper. Thornley et al. 2019. JAntimicrobChemother Antibiotic	Jan-19	31/05/2019	Jan-19	Declare and participate at the chair's discretion.

	Committee Member	professional and personal	prescribing for residents in long-term-care facilities across the UK				
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Research paper Beovic et al. 2018. IntJAntimicrobAgents Legal framework of antimicrobial stewardship in hospitals (LEASH): a European Society of Clinical Microbiology and Infectious Diseases (ESCMID) cross-sectional international survey	2018	31/05/2019	2018	Declare and participate at the chair's discretion.
Philip Howard	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Islam, J et al 2018. A national quality incentive scheme to reduce antibiotic overuse in hospitals; evaluation of perceptions and impact. J Antimicrob Chemother	2018	31/05/2019	2018	Declare and participate at the chair's discretion.
Amelia Joseph	PHAC D Advisory Committee Member	Direct - financial/non-financial Indirect interests	None	N/A	04/06/2019	N/A	N/A
Marisa Lanzman	PHAC D Advisory Committee Chair	Direct - financial	Co-author for a chapter on 'Sepsis in Adults' in 'Drugs in Use' 6th Edition. Remuneration = £125	07/09/2020	07/09/2020	Ongoing	Declare and participate.
Marisa Lanzman	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	Presentation on NICE guidelines to the Clinical Pharmacy Congress 2020	Jun-20	Nov-20	Ongoing	Declare and participate.
Marisa Lanzman	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	Member of the Sepsis Collaborative advisory committee	Feb-20	Feb-20	Ongoing	Declare and participate.
Marisa Lanzman	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	Member of the UK Clinical Pharmacist Association – Pharmacy Infection Network Committee which organises an annual conference with some sponsorship from a number of pharmaceutical companies	15/08/2018	22/07/2019	Ongoing	Declare and participate at the chair's discretion.
Tessa Lewis	PHAC D Advisory	Direct - non-financial	Guest speaker on The Aural Apothecary podcast	2021	11/05/2021	28/05/2021	Declare and participate



	Committee Chair	professional and personal					
Tessa Lewis	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	RCGP conference presentation "Rapid update on skin infections - Incorporating NICE/PHE guidelines into daily general practice." No payment received	11/02/2021	11/02/2021	11/02/2021	Declare and participate
Paddy McMaster	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	UK and Ireland Good Practice Recommendations for improving antimicrobial stewardship and promoting safe ambulation of children presenting with common infections to secondary care hospitals. Contributing towards writing antimicrobial stewardship guidance.	30/08/2019	30/08/2019	Ongoing	Declare and participate at the chair's discretion
Paddy McMaster	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	Membership of UK Paediatric Antimicrobial Stewardship (UK-PAS) Network	30/08/2019	30/08/2019	Ongoing	Declare and participate.
Paddy McMaster	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	UK and Ireland Good Practice Recommendations for improving antimicrobial stewardship and promoting safe ambulation of children presenting with common infections to secondary care hospitals. Contributing towards writing antimicrobial stewardship guidance.	30/08/2019	30/08/2019	Ongoing	Declare and participate.
Paddy McMaster	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	Principal investigator for BATCH study (procalcitonin)	22/07/2019	23/07/2019	Ongoing	Declare and participate at the chair's discretion.
Paddy McMaster	PHAC D Advisory Committee Chair	Indirect	Northwest paediatric infectious diseases study day- sponsorship for lunch in exchange for a desk at the day.	19/06/2019	18/06/2019	26/09/2019	Declare and participate at the chair's discretion.
Paddy McMaster	PHAC D Advisory Committee Chair	Direct - non-financial professional and personal	Lead author for Northwest paediatric infectious guidelines which APGs will feed into.	18/06/2019	18/06/2019	Ongoing	Declare and participate.

Cliodna McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Observer on BSAC Council	2009	07/10/2016	Oct-18	Declare and participate at the chair's discretion
Cliodna McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	European Centre for Disease Prevention and Control expert advisor on Antimicrobial Stewardship	2008	01/05/2018	Ongoing	Declare and participate at the chair's discretion
Cliodna McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Member of ESPAUR and PHE AMR Programme Board	2015	07/10/2016	Ongoing	Declare and participate at the chair's discretion
Cliodna McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Member of UK Diagnostic Stewardship Collaborative	2017	01/05/2018	Ongoing	Declare and participate
Cliodna McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Leads the development of national Public Health England antibiotic and lab use guidance for GPs which covers the diagnosis and treatment of infections	1998	07/10/2016	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to interest declared.
Cliodna McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Has received grants from several publically funded research bodies	1986	07/10/2016	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to interest declared.

Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Lead in the development of TARGET and promotes the TARGET resources hosted by the RCGP which encourages appropriate antibiotic use	2009	07/10/2016	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to interest declared.
Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Leads the e-Bug project	1998	01/02/2017	Ongoing	Declare and participate at the chair's discretion
Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Co-authored papers on the fever PAIN score in general practice – lead author Paul Little	2008	18/05/2017	2013	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to interest declared.
Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Has spoken at antimicrobial resistance symposiums sponsored by public bodies	1998	07/10/2016	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to published papers.

Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Lecky DM, Nakiboneka-Ssenabulya D, Nichols T, Hawkey P, Turner K, Chung K-T, Thomas M, Thomas HL, McCrae L, Shabir S, Manzoor S, Alvarez-Buyella A, Smith S and McNulty CAM. Informing future research for carriage of multi-resistant gram negative bacteria: Problems with recruiting to an English stool sample community prevalence study. <i>BMJ Open</i> 2017; 7:e017947.	2017	10/05/2019	2017	Declare and participate
Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Lecky DM, Hawking MK, McNulty CA, group Es. Patients' perspectives on providing a stool sample to their GP: a qualitative study. <i>The British journal of general practice : the journal of the Royal College of General Practitioners.</i> 2014;64(628):e684-693.	2014	10/05/2019	2014	Declare and participate
Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	McNulty CA, Lasseter G, Newby K, Joshi P, Yoxall H, Kumaran K, O'Brien SJ, Evans M. Stool submission by general practitioners in SW England - when, why and how? A qualitative study. <i>BMC family practice.</i> 2012;13:77.	2008	10/05/2019	2012	Declare and participate
Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Royal College of General Practitioners diarrhoea module. This course describes common presentations of diarrhoea infections and outlines their management.	2006	10/05/2019	Ongoing	Declare and participate
Cliona McNulty	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Involvement in Public Health England guidance on infectious diarrhoea – the role of microbiological examination of faeces	2015	10/05/2019	ongoing	Declare and participate

Albany Meikle	Technical Analyst, NICE	Indirect	Father employed by and holds shares in pharmaceutical company F. Hoffmann-La Roche	29/09/2016	01/06/2018	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to interest declared.
John Morris	PHAC D Advisory Committee Member	Direct - financial	Member of the NICE Public Involvement Programme Expert Panel.	Jul-20	01/09/2020	Ongoing	Declare and participate.
John Morris	PHAC D Advisory Committee Member	Direct - financial	Commissioned to write Scottish Handbook of Inherited Bleeding Disorders for Haemophilia Scotland	26/09/2016	18/06/2017	05/08/2020	Declare and participate
John Morris	PHAC D Advisory Committee Member	Direct - financial	Lay member of NICE Technology Appraisals Appeals Committee	05/09/2011	19/08/2017	Ongoing	Declare and participate
John Morris	PHAC D Advisory Committee Member	Direct - financial	Attendance at Preserving Antibiotics through Safe Stewardship Primary Care stakeholders' workshop, 19 Nov 2019 (honorarium paid)	24/10/2019	30/10/2019	Ongoing	Declare and participate.
Mitul Patel	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Paediatric antibiotic stewardship programmes in the UK's regional children's hospitals. S. Vergnano, A. Bamford,..M. Patel,..S. Patel. The Journal of Hospital Infections. August 2020. vol:105 (4); 736-740	Aug-20	09/09/2020	Aug-20	Declare and participate.
Mitul Patel	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Clinical and cost-effectiveness of antimicrobial stewardship programmes. Pooja Shivananda Siddhi, Mitul Patel Journal of the Academy of Clinical Microbiologists, 2019 Volume: 21 Issue: 2 Page: 60-65	Oct-20	09/09/2020	Dec-20	Declare and participate.

Mitul Patel	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Antibiotic prescribing for common infections in primary care: the need for individualised guidelines and policies. BMJ paper	06/07/2020	06/07/2020	Ongoing	Declare and participate.
Mitul Patel	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Chair- West Midlands Infection Group. Three scientific and business meetings per year sponsored by various pharmaceutical companies involve in business of antibiotics. All funds go to WMIG bank account. No personal financial benefits received.	2016	09/11/2018	Ongoing	Declare and participate at the chair's discretion
Mitul Patel	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Co-author: Poster presentations on neonatal bacterial and fungal infections at European Academy of Paediatric Societies conferences.	Oct-18	09/11/2018	Feb 19	Declare and participate at the chair's discretion
Mitul Patel	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Several posters at conference and publications in journals, related to infections and antibiotic use. No endorsement of any drug or technology involved. No commercial companies/ interest involved in views and opinion in any of those publications.	Oct-18	12/09/2019	Ongoing	Declare and participate.
Mitul Patel	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Organise Clinical Microbiology and Infection Workshops (annually) overseas (usually in India). Travel and accommodation costs are covered either by local hosts (university/ medical institute/associations) or raised from participants registration fees.	Oct-18	12/09/2019	Ongoing	Declare and participate.
Louise Picton	Senior Medicines Adviser, NICE	Indirect	Husband works for RB (consumer healthcare), manufacturer of nurofen, in a non-health related position and holds shares in RB.	04/12/2014	28/08/2019	Ongoing	Declare and participate at the chair's discretion. The committee member will be asked to leave by the chair for sections of the meeting when recommendations being made relating to interest declared.

Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Expert Panel Member of NICE COVID-19 Rapid Guidelines Expert Panel Vitamin D. Paid Honorarium	Nov 2020	06/01/2021	December 2020	Declare and participate
Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	BMJ Article: 'Advice, not orders'? The evolving legal status of clinical guidelines.	Aug-20	08/09/2020	Aug-20	Declare and participate.
Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - financial	Member of the NICE Public Involvement Programme Expert Panel.	Jul-20	23/10/2020	Ongoing	Declare and participate.
Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - financial	Member of the NICE COVID-19 Rapid Guidelines Expert Panel, Systemic Anti-cancer Treatment or radiotherapy on the risk of severe illness or death in patients with cancer and COVID-19.	Jun-20	17/09/2020	February 2021	Declare and participate.
Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - financial	Standing Lay Member NHS Same Day Emergency Care Programme Board. Paid honorarium	Aug-19	06/01/2021	Ongoing	Declare and participate.
Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - financial	Lay Member of the NICE Shared Decision-Making Guideline Committee. Paid honorarium.	Nov-18	05/11/2018	February 2021	Declare and participate
Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - financial	Consultancy work regarding development of leadership programmes for doctors in training and other health professionals, Health Education England Leadership Academy. Paid consultancy rate	Aug-18	11/09/2018	Ongoing	Declare and participate
Carole Pitkeathley	PHAC D Advisory Committee Member	Direct - financial	Member of the Leadership Development in Postgraduate Medical Training National Leads Group, Health Education England. Honorarium received.	Apr-18	10/06/2018	Ongoing	Declare and participate

Avril Tucker	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Opinion piece on Antimicrobial Resistance published in 'The People's Friend'	Nov-19	21/11/2019	Nov-19	Declare and participate at the chair's discretion.
Avril Tucker	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Academic poster at FIP World Congress of Pharmacy and Pharmaceutical Sciences: Taking a cluster approach to addressing high rates of co-amoxiclav prescribing in primary care.	May-18	11/05/2018	May-18	Declare and participate at the chair's discretion
Avril Tucker	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Academic poster at FIP World Congress of Pharmacy and Pharmaceutical Sciences: Using marshmallows to engage the public and improve knowledge of AMR	May-18	11/05/2018	May-18	Declare and participate at the chair's discretion
Avril Tucker	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Academic poster at FIP World Congress of Pharmacy and Pharmaceutical Sciences: From Marshmallows to Magic: engaging the public to reduce AMR	May-18	11/05/2018	May-18	Declare and participate at the chair's discretion
Avril Tucker	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	Academic poster at FIP World Congress of Pharmacy and Pharmaceutical Sciences: Using e-Bug to raise awareness of infection in foundation phase school children: a pilot study.	May-18	11/05/2018	May-18	Declare and participate at the chair's discretion
Caroline Ward	PHAC D Advisory Committee Member	Direct - financial/non-financial Indirect interests	None	N/A	29/03/2019	N/A	N/A
Nirouz Zarroug	PHAC D Advisory Committee Member	Direct - non-financial professional and personal	MRes: The effects of prebiotic consumption on adults with gastrointestinal infection and gastrointestinal inflammation: A Systematic Review. Scholarship Sponsored by the Royal Liverpool University Hospital	2017	06/12/2019	Ongoing	Declare and participate.



## External expert reviewer and expert witness

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Destiny Pharma consulting fees relating to NTCD (treatment of CDI).	2021	02/07/2021	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Johnson S, Lavergne V, Skinner AM et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Jun 24;ciab549. doi: 10.1093/cid/ciab549.	Jun-21	01/07/2021	Jun-21
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Zhao H, Nickle DC, Zeng Z et al. Global Landscape of Clostridioides Difficile Phylogeography, Antibiotic Susceptibility, and Toxin Polymorphisms by Post-Hoc Whole-Genome Sequencing from the MODIFY I/II Studies. Infect Dis Ther. 2021 Jun;10(2):853-870. doi: 10.1007/s40121-021-00426-6.	Jun-21	01/07/2021	Jun-21
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Charmaine N, Ines B M, Jessica A B et al. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. NPJ Biofilms Microbiomes. 2021 Feb 5;7(1):16. doi: 10.1038/s41522-021-00184-w.	Feb-21	04/03/2021	Feb-21
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Buckley AM, Moura IB, Wilcox MH. Is there a causal relationship between trehalose consumption and Clostridioides difficile infection? Curr Opin Gastroenterol. 2021 Jan;37(1):9-14. doi: 10.1097/MOG.0000000000000695.	Jan-21	08/01/2021	Jan-21
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Harris HC, Best EL, Normington Cet al. Optimization of an Assay To Determine Colonization Resistance to Clostridioides difficile in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01401-20. doi: 10.1128/AAC.01401-20.	Dec-20	08/01/2021	Dec-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Azimirad M, Krutova M, Yadegar A et al. (2020) Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2016: a 14-year-long cross-sectional study Emerging Microbes and Infection Dec;9(1):1432-43. doi: 10.1080/22221751.2020.1780949.	Dec-20	25/09/2020	Dec-20

Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Novakova E, Kotlebova N, Gryndlerova A et al. An Outbreak of Clostridium (Clostridioides) difficile Infections within an Acute and Long-Term Care Wards Due to Moxifloxacin-Resistant PCR Ribotype 176 Genotyped as PCR Ribotype 027 by a Commercial Assay. J Clin Med. 2020 Nov 20;9(11):3738. doi: 10.3390/jcm9113738.	Nov-20	08/01/2021	Nov-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Widmer AF, Frei R, Kuijper EJ et al. (2020) Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland. Emerging Infectious Diseases 26 (10): 2370-7. doi: 10.3201/eid2610.190804.	Oct-20	25/09/2020	Oct-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Jones WS, Rice S, Power HM et al. (2020) Cost Consequences for the NHS of Using a Two-Step Testing Method for the Detection of Clostridium difficile with a Point of Care, Polymerase Chain Reaction Test as the First Step. Diagnostics (Basel) Oct 14 10(10): E819. doi: 10.3390/diagnostics10100819.	Oct-20	25/09/2020	Oct-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Bassères E, Begum K, Lancaster C et al. (2020) In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. Journal of Antimicrobial Chemotherapy Oct 1;75(10):2879-84. doi: 10.1093/jac/dkaa289.	Oct-20	25/09/2020	Oct-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Roberts AK, Harris HC, Smith M et al. (2020) A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models. Frontiers in Microbiology Sep 22;11:578903. doi: 10.3389/fmicb.2020.578903. eCollection 2020.	Sep-20	25/09/2020	Sep-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Buckley AM, Altringham J, Clark E et al. (2020) Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model. Journal of Antimicrobial Chemotherapy Sep 15:dkaa386. doi: 10.1093/jac/dkaa386. Online ahead of print.	Sep-20	25/09/2020	Sep-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Davies K, Mawer D, Walker AS et al. An Analysis of Clostridium difficile Environmental Contamination During and After Treatment for C difficile Infection. Open Forum Infect Dis. 2020 Aug 17;7(11):ofaa362. doi: 10.1093/ofid/ofaa362.	Aug-20	08/01/2021	Aug-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Goldstein EJC, Citron DM, Gerding DN, et al. (2020) Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data from the Randomized Phase III Trial, MODIFY II. Clinical Infectious Diseases. Aug 14;71(4): 1102-5. doi: 10.1093/cid/ciz1151.	Aug-20	25/09/2020	Aug-20
Mark Wilcox	External expert	Direct - non-financial	Begum K, Bassères E, Miranda J, Lancaster C et al. (2020) In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators	Jul-20	25/09/2020	Jul-20

	reviewer and expert witness	professional and personal	against Clostridioides difficile. Antimicrobial Agents and Chemotherapy Jul 22 64(8): e00522-20. doi: 10.1128/AAC.00522-20.			
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Johnson S, Citron DM, Gerding DN et al. (2020) Efficacy of bezlotoxumab in trial participants infected with Clostridioides difficile strain BI associated with poor outcomes. Clinical Infectious Diseases Jul 31: ciaa1035. doi: 10.1093/cid/ciaa1035.	Jul-20	25/09/2020	Jul-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Davies K, Lawrence J, Berry C et al. (2020) Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Frontiers in Public Health Jul 17;8:293. doi: 10.3389/fpubh.2020.00293. eCollection 2020.	Jul-20	25/09/2020	Jul-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Kelly CP, Poxton IR, Shen J, et al. (2020) Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile. Infection Clinical Infectious Diseases. Jun 24;71(1): 81-6. doi: 10.1093/cid/ciz809.	Jun-20	25/09/2020	Jun-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Sandlund J, Davies K, Wilcox MH (2020) Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic Accuracy. Journal of Clinical Microbiology May 26;58 (6): e01913-19. doi: 10.1128/JCM.01913-19. Print 2020 May 26.	May-20	25/09/2020	May-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Shen J, Mehrotra DV, Dorr MB et al. (2020) Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment mSphere May 6;5(3): e00232-20. doi: 10.1128/mSphere.00232-20.	May-20	25/09/2020	May-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Monaghan TM, Sloan TJ, Stockdale SR, Blanchard AM et al. (2020) Metagenomics reveals impact of geography and acute diarrheal disease on the Central Indian human gut microbiome. Gut Microbes May 27:1-24. doi: 10.1080/19490976.2020.1752605.	May-20	25/09/2020	May-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Wilcox MH, McGovern BH, Hecht GA. (2020) The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis. Open Forum Infectious Diseases. Apr 11;7(5): ofaa114. doi: 10.1093/ofid/ofaa114. eCollection 2020 May.	Apr-20	25/09/2020	May-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Guery B, Georgopali A, Karas A et al. (2020) Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial. Journal of	Apr-20	25/09/2020	Apr-20

			Antimicrobial Chemotherapy Apr 1;75 (4):1014-18. doi: 10.1093/jac/dkz549.			
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	MacGowan A, Grier S, Stoddart M et al. [2020] Impact of rapid microbial identification on clinical outcomes in bloodstream infection: the RAPIDO randomized trial. <i>Clinical Microbiology and Infection</i> Oct;26(10):1347-54. doi: 10.1016/j.cmi.2020.01.030. Epub 2020 Mar 25.	Mar-20	25/09/2020	Oct-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Davies K, Davis G, Barbut F et al. (2020) Factors affecting reported <i>Clostridioides difficile</i> infection rates; the more you look the more you find, but should you believe what you see? <i>Anaerobe</i> Apr 62:102178. doi: 10.1016/j.anaerobe.2020.102178. Epub 2020 Feb 22	Feb-20	25/09/2020	Apr-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Chilton CH, Crowther GS, Miossec C et al. (2020) Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated <i>Clostridioides (Clostridium) difficile</i> infection (CDI) in an in vitro human gut model <i>Journal of Antimicrobial Chemotherapy</i> Jun 1;75(6):1458-65. doi: 10.1093/jac/dkaa062.	Feb-20	25/09/2020	Jun-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Moura IB, Normington C, Ewin D et al. (2020) Method comparison for the direct enumeration of bacterial species using a chemostat model of the human colon. <i>BMC Microbiology</i> Jan 2;20(1): 2. doi: 10.1186/s12866-019-1669-2	Jan-20	25/09/2020	Jan-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Wilcox MH (2020) Caution is warranted in using cephamycin antibiotics against recurrent <i>Clostridioides difficile</i> infection. <i>Nature Microbiology</i> Feb 5(2):236. doi: 10.1038/s41564-019-0661-9. Epub 2020 Jan 27.	Jan-20	25/09/2020	Jan-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Freeman J, Vernon J, Pilling S et al. (2020) Five-year Pan-European, longitudinal surveillance of <i>Clostridium difficile</i> ribotype prevalence and antimicrobial resistance: the extended ClosER study. <i>European Journal of Clinical Microbiology &amp; Infectious Diseases</i> . 2020 Jan;39(1):169-77. doi: 10.1007/s10096-019-03708-7. Epub 2019 Dec 7.	Dec-19	25/09/2020	Dec-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Zeng Z, Zhao H, Dorr MB, et al. (2020) Bezlotoxumab for prevention of <i>Clostridium difficile</i> infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. <i>Anaerobe</i> . Feb 61: 102137. Epub 2019 Dec 14. doi: 10.1016/j.anaerobe.2019.102137.	Dec-19	25/09/2020	Feb-20
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Eyre DW, Peto TEA, Crook DW, et al. (2019) Hash-Based Core Genome Multilocus Sequence Typing for <i>Clostridium difficile</i> <i>Journal of Clinical Microbiology</i> . Dec 23;58(1): e01037-19. doi: 10.1128/JCM.01037-19. Print 2019 Dec 23.	Dec-19	25/09/2020	Dec-19
Mark Wilcox	External expert	Direct - non-financial	Wilcox MH, Cornely OA, Guery B et al. (2019) Microbiological Characterization and Clinical Outcomes After Extended-Pulsed	Nov-19	25/09/2020	Nov-19

	reviewer and expert witness	professional and personal	Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study. Open Forum Infectious Diseases. Nov 6;6(11): ofz436. doi: 10.1093/ofid/ofz436. eCollection 2019 Nov.			
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Sandlund J, Wilcox MH. (2019) Reply to Tenover et al., "Guidelines Support the Value of Stand-Alone Nucleic Acid Amplification Tests for Clostridioides (Clostridium) difficile Infection." Journal of Clinical Microbiology. Sep 24;57(10): e01157-19. doi: 10.1128/JCM.01157-19. Print 2019 Oct.	Sep-19	25/09/2020	Oct-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Pickering DS, Vernon JJ, Freeman J et al. (2019) Investigating the transient and persistent effects of heat on Clostridium difficile spores Journal of Medical Microbiol. 2019 Oct;68(10):1445-54. Epub 2019 Aug 8. doi: 10.1099/jmm.0.001048.	Aug-19	25/09/2020	Aug-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Wilcox MH, Rahav G, Dubberke ER, et al. (2019) Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. Open Forum Infectious Diseases. Aug 1;6(8): ofz293. doi: 10.1093/ofid/ofz293.	Aug-19	25/09/2020	Aug-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Krutova M, Wilcox MH, Kuijper EJ. (2019) A two-step approach for the investigation of a Clostridium difficile outbreak by molecular methods. Clinical Microbiology and Infection. Nov 25(11): 1300-01. doi: 10.1016/j.cmi.2019.07.022. Epub 2019 Jul 29.	Jul-19	25/09/2020	Nov-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Kong LY, Davies K, Wilcox MH. (2019) The perils of PCR-based diagnosis of Clostridioides difficile infections: Painful lessons from clinical trials Anaerobe 2019. Dec; 60:102048. Epub 2019 Jun 12. doi: 10.1016/j.anaerobe.2019.06.001.	Jun-19	25/09/2020	Jun-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Mawer D, Byrne F, Drake S, et al. (2019) Cross-sectional study of the prevalence, causes and management of hospital-onset diarrhoea. The Journal of Hospital Infection. Oct 103(2): 200-09. doi: 10.1016/j.jhin.2019.05.001. Epub 2019 May 8.	May-19	25/09/2020	Oct-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Sandlund J, Wilcox MH. (2019) Ultrasensitive Detection of Clostridium difficile Toxins Reveals Suboptimal Accuracy of Toxin Gene Cycle Thresholds for Toxin Predictions. Journal of Clinical Microbiology. May 24;57(6): e01885-18. doi: 10.1128/JCM.01885-18. Print 2019 Jun.	May-19	25/09/2020	Jun-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Dayananda P, Wilcox MH. (2019) A Review of Mixed Strain Clostridium difficile Colonization and Infection. Frontiers in Microbiology. Apr 10;10: 692. doi: 10.3389/fmicb.2019.00692. eCollection 2019.	Apr-19	25/09/2020	Apr-19

Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Eyre DW, Didelot X, Buckley AM, et al. (2019) Clostridium difficile trehalose metabolism variants are common and not associated with adverse patient outcomes when variably present in the same lineage. EBioMedicine. May; 43: 347-55. doi: 10.1016/j.ebiom.2019.04.038. Epub 2019 Apr 27.	Apr-19	25/09/2020	May-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Vernon JJ, Wilcox MH, Freeman J. (2019) Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness. Journal of Antimicrobial Chemotherapy Apr 1;74(4): 877-84. doi: 10.1093/jac/dky535.	Apr-19	25/09/2020	Apr-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Dingle KE, Didelot X, Quan TP, et al. (2019) A Role for Tetracycline Selection in Recent Evolution of Agriculture-Associated Clostridium difficile PCR Ribotype 078. mBio. Mar 12;10(2): e02790-18. doi: 10.1128/mBio.02790-18.	Mar-19	25/09/2020	Mar-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Gerding DN, Cornely OA, Grill S et al. (2019) Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. The Lancet Infectious Diseases. Mar;19(3): 265-74. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29.	Feb-19	25/09/2020	Feb-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Dayananda P, Wilcox MH. (2019) Irritable bowel syndrome following Clostridium difficile infection. Current Opinion in Gastroenterology. Jan 35(1):1-5. doi: 10.1097/MOG.0000000000000490.	Jan-19	25/09/2020	Jan-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Wilcox MH, Rooney CM. (2019) Comparison of the 2010 and 2017 Infectious Diseases Society of America guidelines on the diagnosis and treatment of Clostridium difficile infection. Current Opinion in Gastroenterology Jan;35(1): 20-4. doi: 10.1097/MOG.0000000000000489.	Jan-19	25/09/2020	Jan-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Moura IB, Buckley AM, Ewin D, et al. (2019) Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon. Antimicrobial Agents and Chemotherapy. Jan 29;63(2): e01581-18. doi: 10.1128/AAC.01581-18. Print 2019 Feb.	Jan-19	25/09/2020	Feb-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Diniz AN, de Oliveira Júnior CA, Vilela EG, et al. (2019) Molecular epidemiology of Clostridioides (previously Clostridium) difficile isolates from a university hospital in Minas Gerais, Brazil. Anaerobe. Apr; 56:34-9. doi: 10.1016/j.anaerobe.2019.01.010. Epub 2019 Jan 29.	Jan-19	25/09/2020	Apr-19

Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Kong LY, Eyre DW, Corbeil J et al. (2019) Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing. Clinical Infectious Diseases. Jan 7 68(2): 204-9. doi: 10.1093/cid/ciy457.	Jan-19	25/09/2020	Jan-19
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Davies KA, Planche T, Wilcox MH. (2018) The predictive value of quantitative nucleic acid amplification detection of Clostridium difficile toxin gene for faecal sample toxin status and patient outcome. PLoS One. Dec 5;13(12):e0205941. doi: 10.1371/journal.pone.0205941.	Dec-18	25/09/2020	Dec-18
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Leong HN, Kurup A, Tan MY et al. (2018) Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics Infection and Drug Resistance. Oct 25(11): 1959-74. doi: 10.2147/IDR.S172366. eCollection 2018.	Nov-18	25/09/2020	Nov-18
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Pickering DS, Wilcox MH, Chilton CH. (2016) Biofilm-derived spores of Clostridioides (Clostridium) difficile exhibit increased thermotolerance compared to planktonic spores. Anaerobe. Dec;54:169-171. Epub 2016 Oct 5. doi: 10.1016/j.anaerobe.2016.10.003.	Oct-18	25/09/2020	Dec-18
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Martin JSH, Eyre DW, Fawley WN, et al. (2016) Patient and Strain Characteristics Associated With Clostridium difficile Transmission and Adverse Outcomes. Clinical Infectious Diseases. Oct 15;67(9): 1379-87. doi: 10.1093/cid/ciy302.	Oct-18	25/09/2020	Oct-18
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Kelly CP, Wilcox MH, Glerup H, et al. (2016) Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease. Gastroenterology. Oct;155 (4):1270-1. doi: 10.1053/j.gastro.2016.06.080. Epub 2016 Sep 15.	Sep-18	25/09/2020	Oct-18
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Kociolek LK, Perdue ER, Fawley WN, et al. (2018) Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains. Anaerobe. Dec; 54:1-7. Epub 2018 Aug 3. doi: 10.1016/j.anaerobe.2016.07.004.	Aug-18	25/09/2020	Dec-18
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Beinortas T, Burr NE, Wilcox MH et al. (2018) Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. The Lancet Infectious Diseases. Sep;18(9): 1035-44. doi: 10.1016/S1473-3099(18)30285-8. Epub 2016 Jul 17.	Jul-18	25/09/2020	Jul-18
Mark Wilcox	External expert	Direct - non-financial	Eyre DW, Davies KA, Davis G et al. (2018) Two Distinct Patterns of Clostridium difficile Diversity Across Europe Indicating Contrasting	Apr-18	25/09/2020	Apr-18

	reviewer and expert witness	professional and personal	Routes of Spread. Clinical Infectious Diseases. Sep 14;67(7): 1035-44. doi: 10.1093/cid/ciy252.			
Mark Wilcox	External expert reviewer and expert witness	Direct - non-financial professional and personal	Salazar CL, Reyes C, Cienfuegos-Gallet AV, et al. (2016) Subtyping of Clostridium difficile PCR ribotypes 591,106 and 002, the dominant strain types circulating in Medellin, Colombia. PLoS One. Apr 12 13(4): e0195694. doi: 10.1371/journal.pone.0195694.	Apr-18	25/09/2020	Apr-18
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	EnteroBiotix - Consulting fees and research funding relating to whole community, intestinal microbiome medicinal product / FMT (treatment of CDI).	2020	20/08/2020	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Crestone - Consulting fees relating to CRS3123 (treatment of CDI).	2019	20/08/2020	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Vaxxilon – renamed Idorsia. Consulting fees relating to CD vaccine (prevention of CDI).	2019	23/05/2019	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Pfizer consulting fees and research funding relating to CD vaccine (prevention of CDI).	2016	23/05/2019	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Seres consulting fees, lecture fees and research funding relating to SER-109 (treatment of recurrent CDI).	2015	23/05/2019	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Valneva consulting fees relating to CD vaccine (prevention of CDI).	2015	23/05/2019	2018
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Da Volterra consulting fees and research funding relating to DAV-131 (prevention of CDI).	2014	23/05/2019	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Merck consulting fees, lecture fees and research funding relating to bezlotoxumab.	2014	23/05/2019	Ongoing



Mark Wilcox	External expert reviewer and expert witness	Direct - financial	MicroPhram research funding relating to polyclonal antibody for treatment of severe CDI.	2014	23/05/2019	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Summit consulting fees, lecture fees and research funding relating to ridnilazole (treatment of CDI).	2012	23/05/2019	Ongoing
Mark Wilcox	External expert reviewer and expert witness	Direct - financial	Synthetic Biologics consulting fees and lecture fees relating to SYN-004 (prevention of CDI).	2012	23/05/2019	2018